The Swiss pharma company Novartis ranks in the top 10 of pharma companies, and boasts drugs ranging from Ritalin and Lamisil to clozapine, Diovan and Gilenya. It also owns the generic giant Sandoz. Unlike its competitor, GlaxoSmithKline, Novartis did not offer free flu vaccines during the H1N1 flu epidemic.

In March 2011, Novartis gained FDA approval for Gilenya, its multiple sclerosis drug. The nod came on the heels of a narrower EMA approval, which grants second-line treatment status. According to experts, the drug could be worth $3 billion in annual sales as the first oral MS drug on the market.

Novartis purchased the remaining portion of eye care company Alcon in a $12.9 billion deal at the end of 2010, marking the end of one of the biggest battles in biopharma. Although many analysts predicted heavy layoffs in 2010 from the company, only 1,400 jobs were cut in December 2010, with the disclaimer that more could be on the way as Novartis, like others in the industry, analyzes its efficiency.

Tag:

Novartis

Latest Headlines

Latest Headlines

Novartis faces suspension in Japan after series of trial data scandals

SINGAPORE-- Japan plans to temporarily suspend Novartis' pharma business in that country, according to media reports. The Ministry of Health, Labour and Welfare's order will last about 15 days and will cite repeated violations of failure to report adverse events properly, the Japan Times says.

Novartis' Bexsero picks up FDA nod--but with competition looming, approval isn't everything

After years of pinning its vaccine ambitions on meningitis B shot Bexsero, Novartis' FDA approval is here. But as it prepares to fork over the jab--along with the bulk of its vaccines business--to deal partner GlaxoSmithKline, there are other hurdles in the way of its success--including some new competition from Pfizer.

GSK to divest meningitis shots in exchange for EU clearance of Novartis deal

The European Commission has cleared GlaxoSmithKline's deal for most of Novartis' vaccines unit--on a couple of conditions.

Novartis braces for psoriasis pricing war as it preps for Cosentyx launch

Novartis' Cosentyx may be the first next-gen psoriasis treatment to hit the U.S. market, but it certainly won't be the last--and the Swiss drugmaker knows it. So while competitors usher their own prospects down the regulatory pathway, the company is girding for the price war it envisions in its future.

Novartis points to PhIII data to explain weak Jetrea sales

Novartis has admitted that sales of the vitreomacular adhesion drug it licensed from ThromboGenics have failed to live up to expectations. And while various theories have been put forward to explain the drug's relative lack of commercial success, Novartis thinks part of the issue dates back to clinical trials.

Novartis revs up Cosentyx launch as it braces for a psoriasis pricing war

Novartis' Cosentyx may be the first next-gen psoriasis treatment to hit the U.S. market, but it certainly won't be the last--and the Swiss drugmaker knows it. So while competitors usher their own prospects down the regulatory pathway, the company is girding for the price war it envisions in its future.

Novartis eyes more cost-cutting moves to deliver faster-growing profits

Novartis is looking for big things as it doubles down in oncology, hives off vaccines, and teams up with GlaxoSmithKline on consumer health. It's looking for impressive results from its new meds, especially its forthcoming heart failure drug LCZ696 and brand-new psoriasis med Cosentyx. And it's thinking that these changes will help it bear the battering from generic competition.

Novartis, Pfizer and Bristol-Myers hit the gas on R&D last year

Three of the world's largest drugmakers dialed up their R&D budgets in 2014, as Novartis, Pfizer and Bristol-Myers Squibb spent big on costly late-stage programs with hopes of delivering blockbuster new treatments in the coming year.

Psoriasis researchers identify a lineup of suspect proteins behind disease progression

The recent approval of Novartis' Cosentyx marks the first in a whole new lineup of psoriasis drugs coming into the market. But there's still no cure and only a hazy understanding of the root causes of psoriasis. But scientists at Case Western Reserve say they've identified four proteins that they believe may contribute to the disease.

Novartis Q4 profit slumps nearly 27% as sales take a hit

Swiss-based Novartis reported a nearly 27% drop in fourth-quarter profit on Tuesday as lower-than-expected sales hit the bottom line.